MiMARK
- hard tech
- biotechnology
- horizon europe
- woman founder
- spinout
- eit ecosystem
- oncology
- eit health
- femtech
- eit supernovas
- eicfund
- medical diagnostics
- bootcamps (eit health)
- biomarkers
- bootcamp 2018 (eit health)
- women's health
- gynaecological health
- caixa impulse (eit health)
- wild card (eit health)
- wild card 2020 (eit health)
- caixa impulse 2016 (eit health)
Date | Investors | Amount | Round |
---|---|---|---|
€70.0k | Grant | ||
€10.0k | Grant | ||
€1.5m | Grant | ||
N/A | Spinout | ||
€2.5m | Grant | ||
* | €1.0m | Seed | |
* | €4.2m | Seed | |
Total Funding | AUD15.8m |
Recent News about MiMARK
EditAt MiMARK we envision the gynecological fluid as the next liquid biopsy in gynecology, to develop pain-free, accurate, and accessible diagnostic solutions.
Our 1st product, WomEC, is an IVD assay for diagnosing Endometrial Cancer (EC). Every year, 70M women worldwide presenting with abnormal uterine bleeding will undergo a multistep and inaccurate diagnostic journey.
EC diagnosis failure has dramatic consequences: invasive procedures are needed, and the patient has the risk of receiving sub-optimal surgery.
With WomEC we will have 99% diagnosis without invasive procedures and guide optimal surgery. WomEC has been verified in 5 independent clinical retrospective studies involving +600 patients.
The company was incorporated in January 2021. MiMARK was the winning company in the EIT Health Wild Card competition and was awarded 1.5M€. As of today, the company has nearly gained 5M€ in competitive national and European funding (including the competitive European grant, EIC Accelerator). In addition, the company closed a successful 1.7 million EUR funding seed round.
Keywords: Pharmaceuticals and Biotechnology, Cancer Diagnostics, Cancer Treatment, Gynaecological Treatment, Gynecological Care, Health Tech, Pathological Examination, Women's Health.